Milestone Pharma announces positive Phase 3 RAPID trial results for etripamil in PSVT

Milestone Pharmaceuticals Inc.

Primary endpoint met: 64.3% of etripamil patients converted to sinus rhythm within 30 min vs 31.2% placebo (HR=2.62, p<0.001).
Safety profile consistent with prior trials; no serious AEs related to etripamil; majority of AEs mild (68%) to moderate (31%).
Pooled data show statistically significant reduction in medical interventions and ED visits.
Company plans to submit NDA to FDA in mid-2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.